Search PubMed⌕ Search

Biomedical subjects

E Weber

Publications and source records attributed to E Weber.

At least 487 records · Page 27Linked to original sources
PubMed1977

[Oral anticoagulants and platelet function in hypolipemic therapy using a new clofibrate analog (BM 15.075) (author's transl)].

When testing the effect of a new clofibrate analogue (BM 15.075) on oral anticoagulation and blood clotting in 15 patients for over four weeks it was demonstrated that, depending on the dose of the drug, there was an increase in anticoagulation. The dose of phenprocoumon had to be reduced by 20.6 or 28.7%, respectively, when BM 15.075 was given at a dose of 450 or 600 mg. There was an inhibition of collagen-induced platelet-aggregation. In parallel there was an increase in bleeding time. Fibrinogen concentration was slightly but statistically not significantly decreased. Euglobulin lysis was shortened, especially if previously abnormally long. There was no direct influence on other plasmatic clotting factors.

Aged↗
PubMed1977

[A prospective study of post-operative bleeding from stress lesions. I. Epidemiology (author's transl)].

Among 5776 patients operated on under general anaesthesia there was an increased risk of postoperative gastro-intestinal bleeding from stress lesions among those aged over 70 years, after major surgery, or with complications such as hypovolaemia, septicaemia or respiratory failure (n = 551). In this group of patients the incidence of fatal haemorrhage was 0.5%. Stress lesions were a certain cause of bleeding from the gastro-intestinal tract in 5.1% and a probable one in 5.1%. Time of year, sex, past history of peptic ulcer, or anticoagulation did not increase the risk of bleeding.

Adult↗
PubMed1977

[Problems in dose finding from the view of the clinical pharmacologist (author's transl)].

The dose of a drug applied to a patient is determined by his physiological and pathological data, by specific properties of the drug and by the mode of application. The most important physiological data which influence the dose are body weight, sex, age, a pregnancy, genetic variations and circadian rhythm. Pathological findings such as organ insufficiencies (kidneys, heart, liver, endocrinium, transport protein in the blood, etc.) are also to be considered. Particularities of the drug kinetics (insignificant absorption, excessive biological half-life, specific affinities to tissues, etc.), of metabolism (first-pass effect, toxic metabolites, saturable detoxification, stress, etc.) or a high toxicity are other parameters of consequence. Finally attention has to be paid to the mode of application (p.o., i.v., etc.), to the kind of galenic preparation (liquid or solid, slow-releasing preparation, etc.), to interactions if using combinations of drugs and to a long-lasting pharmacotherapy. Aditional problems are encountered in clinical trials especially in early phases while determining the tolerable therapeutic dose.

Adult↗
PubMed1977

[Psychiatrically noticeable anxiety, EEG alpha index, alpha feedback and relaxation].

In a follow-up study (first investigation: KIRSCHBAUM u. GISTL, arch. Psychol. 1973, 125, 263-273) fifteen patients with psychiatric or neurological disorders were examined for correlations between anxiety (clinical rating), scores from MAS and MMQ, and EEG-Alpha-percentage alterations during an unspecific relaxation training with or without Alpha-Biofeedback. Clinically and psychometrically high anxious patients (n = 10) showed under both conditions significant diminuation of Alpha-percentage in contrast to earlier examined students whose Alpha-rates had increased (significantly). Theoretical explanations of these results are discussed.

Adult↗
PubMed1976

Serum digoxin levels in patients of a general practice in Germany.

Serum digoxin levels were determined in 33 outpatients of a general practice in the countryside, on three occasions at intervals of 8 weeks. All the patients were on long term digoxin treatment, about 2 years on average. About 14 days after the first and the second visits the results of the measurements were sent to the patients, with a comment about their reliability in taking treatment according to the serum digoxin level. At the first visit half of the serum digoxin level were lower than 0.5 ng/ml; the mean serum concentration was 0.52 ng/ml. There was no correlation between serum concentration and age, dose or creatinine level; but there was with replies to the question about regularity of drug intake. The mean serum level at the second and the third visits was 0.88 ng/ml and 0.89 ng/ml, respectively. A correlation was found between the dose and the serum digoxin level. From these results it seems that compliance by the patient plays a major role in producing steady state levels of drugs.

Aged↗
PubMed1976

[Medical problems in the practical execution of drug testing].

Different experimental designs for a clinical trial have to be applied for every individual substance even if it, though closely related to some other, shows minor differences in its effects. Difficulties which often occur during phase I trials are: the choice of the volunteer, dosage and route of application of the substance, especially in the first trials in humans, the instructions to the volunteer after intake of the drug, increase in dosage, the number of repeating applications and the interval between uptake. Problems arising during phase II, III and IV trials are concerned mainly with controlled clinical trials: choice of the standard treatment or of a placebo, search for the influencing factors, etiology of the symptoms, stage of the illness, control of patient's compliance etc. In contrast to common opinion, clinical trials cannot be considered to be especially dangerous as data show.

Age Factors↗